A detailed history of Comerica Bank transactions in Vaxcyte, Inc. stock. As of the latest transaction made, Comerica Bank holds 273,022 shares of PCVX stock, worth $22.7 Million. This represents 0.12% of its overall portfolio holdings.

Number of Shares
273,022
Previous 273,025 0.0%
Holding current value
$22.7 Million
Previous $20.6 Million 51.19%
% of portfolio
0.12%
Previous 0.09%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$70.52 - $117.12 $211 - $351
-3 Reduced -0.0%
273,022 $31.2 Million
Q2 2024

Aug 15, 2024

BUY
$60.06 - $78.77 $5.1 Million - $6.69 Million
84,941 Added 45.16%
273,025 $20.6 Million
Q1 2024

May 15, 2024

BUY
$59.79 - $81.05 $14,708 - $19,938
246 Added 0.13%
188,084 $12.8 Million
Q4 2023

Feb 14, 2024

BUY
$45.35 - $63.41 $4.6 Million - $6.43 Million
101,407 Added 117.33%
187,838 $11.8 Million
Q3 2023

Nov 21, 2023

BUY
$46.0 - $53.1 $3.98 Million - $4.59 Million
86,431 New
86,431 $4.41 Million

Others Institutions Holding PCVX

About Vaxcyte, Inc.


  • Ticker PCVX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 59,315,100
  • Market Cap $4.94B
  • Description
  • Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine that is in Phase 1/2 clinical trials to treat invasive pneumococcal disease and pneumonia. The company a...
More about PCVX
Track This Portfolio

Track Comerica Bank Portfolio

Follow Comerica Bank and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Comerica Bank, based on Form 13F filings with the SEC.

News

Stay updated on Comerica Bank with notifications on news.